{
    "name": "patiromer",
    "comment": "Rx",
    "other_names": [
        "Veltassa"
    ],
    "classes": [
        "Potassium Binders"
    ],
    "source": "https://reference.medscape.com/drug/veltassa-patiromer-1000043",
    "pregnancy": {
        "common": [
            "Not absorbed systemically following oral administration, and maternal use is not expected to result in fetal risk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to patiromer or its components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Avoid use with severe constipation, bowel obstruction, or impaction, including abnormal postoperative bowel motility disorders; patiromer may be ineffective with these conditions present and may worsen GI conditions",
                "Patients with a history of bowel obstruction or major GI surgery, severe GI disorders, or swallowing disorders were not included in clinical trials",
                "Binds to magnesium in the colon, which can lead to hypomagnesemia; monitor serum magnesium; consider magnesium supplementation if low serum magnesium levels observed "
            ],
            "specific": [
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "Patiromer may potentially bind to some oral co-administered medications, which could decrease their GI absorption and efficacy ",
                        "Binding to other oral medications not listed below may occur if taken too close to patiromer ",
                        "Administer other oral medications at least 3 hr before or after patiromer administration ",
                        "Clinically important interactions ",
                        "Separate administration by at least 3 hr",
                        "Angiotensin II blockers (ARBs; ie, telmisartan only) ",
                        "Beta-blockers (ie, bisoprolol, carvedilol, nebivolol)",
                        "Antibiotics (ie, ciprofloxacin only)",
                        "Levothyroxine ",
                        "Metformin ",
                        "Mycophenolate mofetil ",
                        "Quinidine ",
                        "Thiamine ",
                        "No observed clinically important interactions ",
                        "No separation of dosing is required for these drugs ",
                        "Angiotensin-converting enzyme (ACE) inhibitors (ie, benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril)",
                        "ARBs (ie, azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan) ",
                        "Beta-blockers (ie, metoprolol)",
                        "Loop diuretics (ie, furosemide, bumetanide, torsemide) ",
                        "Antibiotics (ie, trimethoprim, amoxicillin, cephalexin) ",
                        "Mineralocorticoid receptor antagonists (ie, eplerenone, finerenone, spironolactone) ",
                        "Neprilysin inhibitors (ie, sacubitril) ",
                        "SGLT2 inhibitors (ie, canagliflozin, dapagliflozin, empagliflozin) "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "patiromer will decrease the level or effect of bisoprolol by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "patiromer will decrease the level or effect of carvedilol by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "patiromer will decrease the level or effect of ciprofloxacin by  drug binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "patiromer will decrease the level or effect of levothyroxine by  drug binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "patiromer will decrease the level or effect of metformin by  drug binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "patiromer will decrease the level or effect of mycophenolate by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "patiromer will decrease the level or effect of nebivolol by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "patiromer will decrease the level or effect of quinidine by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "patiromer will decrease the level or effect of telmisartan by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiamine",
            "description": {
                "common": "patiromer will decrease the level or effect of thiamine by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration by at least 3 hr from patiromer"
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amoxicillin",
            "description": {
                "common": "patiromer, amoxicillin. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "azilsartan",
            "description": {
                "common": "patiromer, azilsartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benazepril",
            "description": {
                "common": "patiromer, benazepril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "patiromer, bumetanide. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "canagliflozin",
            "description": {
                "common": "patiromer, canagliflozin. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "candesartan",
            "description": {
                "common": "patiromer, candesartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "captopril",
            "description": {
                "common": "patiromer, captopril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cephalexin",
            "description": {
                "common": "patiromer, cephalexin. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dapagliflozin",
            "description": {
                "common": "patiromer, dapagliflozin. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "empagliflozin",
            "description": {
                "common": "patiromer, empagliflozin. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enalapril",
            "description": {
                "common": "patiromer, enalapril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "patiromer, eplerenone. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eprosartan",
            "description": {
                "common": "patiromer, eprosartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "finerenone",
            "description": {
                "common": "patiromer, finerenone. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosinopril",
            "description": {
                "common": "patiromer, fosinopril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "patiromer, furosemide. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irbesartan",
            "description": {
                "common": "patiromer, irbesartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lisinopril",
            "description": {
                "common": "patiromer, lisinopril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "losartan",
            "description": {
                "common": "patiromer, losartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoprolol",
            "description": {
                "common": "patiromer, metoprolol. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moexipril",
            "description": {
                "common": "patiromer, moexipril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "olmesartan",
            "description": {
                "common": "patiromer, olmesartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perindopril",
            "description": {
                "common": "patiromer, perindopril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinapril",
            "description": {
                "common": "patiromer, quinapril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ramipril",
            "description": {
                "common": "patiromer, ramipril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "patiromer, sacubitril/valsartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "spironolactone",
            "description": {
                "common": "patiromer, spironolactone. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "torsemide",
            "description": {
                "common": "patiromer, torsemide. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trandolapril",
            "description": {
                "common": "patiromer, trandolapril. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "patiromer, trimethoprim. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valsartan",
            "description": {
                "common": "patiromer, valsartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Constipation",
            "percent": "7.2"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "5.3"
        },
        {
            "name": "Diarrhea",
            "percent": "4.8"
        },
        {
            "name": "Hypokalemia",
            "percent": "3.5"
        },
        {
            "name": "mEq",
            "percent": "4.7"
        },
        {
            "name": "L",
            "percent": "2.3"
        },
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "Abdominal discomfort",
            "percent": "2"
        },
        {
            "name": "Flatulence",
            "percent": null
        }
    ]
}